RecruitingPhase 3NCT06434753

Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.

Studying Adult hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Intervention
Zinc Acexamate(drug)
Enrollment
300 target
Eligibility
18-80 years · All sexes
Timeline
2022 – 2026

Study locations (1)

Collaborators

Hospital General Universitario Gregorio Marañon · Hospital Vall d'Hebron · Hospital Universitario Puerta del Hierro · Hospital Clinic of Barcelona · Hospital Universitario Central de Asturias · Complejo Hospitalario de Toledo · Germans Trias i Pujol Hospital · Hospital Universitario Marqués de Valdecilla · Hospital Miguel Servet · Parc Taulí Hospital Universitari · Hospital de la Santa creu i Sant Pau - Barcelona · Hospital Universitari de Bellvitge · Hospital del Mar · University Hospital of Girona Dr. Josep Trueta

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06434753 on ClinicalTrials.gov

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adult hepatocellular carcinoma →

← Back to all trials